The surge in chronic kidney disease (CKD) will propel the Dialysis Market during the forecast period.

The global Dialysis Market is valued at USD 111.74 billion in 2023, and is expected to reach USD 145.07 billion by 2030, with a CAGR of 3.8% from 2024 to 2030, according to new research by Next Move Strategy Consulting. The escalating prevalence of chronic kidney disease (CKD) serves as a primary driver fueling the expansion of the dialysis market. The increasing occurrence of predisposing factors such as diabetes and hypertension has notably contributed to the global rise in CKD cases.

With these risk factors becoming more widespread in contemporary lifestyles, a larger portion of the population faces an elevated risk of kidney dysfunction, necessitating renal replacement therapies that include dialysis. The delayed diagnoses, along with the growing burden of non-communicable diseases, and lifestyle-related contributors to CKD led to a significant rise in individuals requiring immediate intervention through dialysis.

Moreover, the progress in healthcare technology plays a pivotal role in propelling significant growth within the dialysis market. This advancement extends life expectancy and enables a broader demographic to live longer with chronic conditions. The introduction of user-friendly home hemodialysis machines, featuring intuitive interfaces and remote monitoring capabilities, has brought about a revolutionary shift in patient care. Patients can now conveniently perform hemodialysis at home, mitigating the necessity for frequent hospital visits.

For instance, Signify Health, a subsidiary of CVS Health, has introduced an extensive in-home assessment for kidney health to enhance its Diagnostic and Preventive Services portfolio. These new screenings serve to broaden Signify Health's array of services. Their aim facilitated the early identification, diagnosis, and care of prevalent causes of illness and death in individuals under Medicare Advantage coverage. As part of an In-home Health Evaluation (IHE), Signify Health providers administer the kidney health assessment, and this service is offered at no extra expense to Medicare Advantage plan members.

However, limited awareness among the general population regarding kidney diseases is a significant impediment to the growth of the dialysis market. On the contrary, the emergence of wearable and portable dialysis devices stands as a groundbreaking advancement in dialysis technology, offering a transformative opportunity for the dialysis market. These compact systems, resembling small backpacks, empower patients with unprecedented mobility and flexibility in their treatment schedules.

Request a sample here: https://www.nextmsc.com/dialysis-market/request-sample

According to the report, leading players in the Dialysis Market include Baxter International, Inc., DaVita Inc., Nikkiso Co. Ltd., NxStage Medical, Inc., Asahi Kasei Corporation, Medicators, Inc, Fresenius Medical Care AG & Co. KGaA, Nipro Corporation, B. Braun Avitum AG, Diaverum Deutschland GmbH, and others.

These market players are adopting strategies such as collaboration and product launches across various regions to maintain their dominance in the Dialysis Market. For instance, in April 2023, Medtronic plc and DaVita Inc. unveiled Mozarc Medical, a new independent company dedicated to transforming kidney health through patient-centric technology solutions. Mozarc Medical aims to pioneer innovative kidney health technologies that enhance the overall patient experience and promote global access to care. 

Also, in August 2022, Fresenius Medical Care North America's Renal Therapies Group introduced Speedswap, an innovative option for the NxStage System One with NxView. This technology allows for the replacement of a flow-compromised dialysis filter without changing the entire cartridge, aiming to minimize therapy downtime, streamline nursing tasks, and cut treatment costs in acute care settings.

In addition, in September 2023, B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy and pain management, received FDA 510(k) clearance for the AQUAbase nX Reverse Osmosis System. This single-stage device ensures high-quality water for dialysis patients without chemical usage. With its unique design, AQUAbase nX boasts a raw water conversion rate of up to 75%, potentially conserving water and reducing costs for power, pre-treatment, and equipment maintenance.

Moreover, in June 2021, Baxter International Inc. introduced Sharesource Analytics 1.0, a cutting-edge digital health solution for home-based peritoneal dialysis (PD) patients. This clinical management resource, part of the Sharesource platform, offers healthcare professionals a simplified dashboard with trend data from patients' home dialysis treatments.

Key Insights from the Dialysis Market Report:

• The information related to key drivers, restraints, and opportunities and their impact on the dialysis market is provided in the report.

• The value chain analysis in the market study provides a clear picture of the roles of each stakeholder.

• The market share of the global dialysis market and their competitive analysis are provided in the report.